肿瘤演化过程中的进化生态：概念、应用与创新

doi:10.16288/j.yczz.24-264

遗传 ›› 2025, Vol. 47 ›› Issue (2): 228-236.doi: 10.16288/j.yczz.24-264

肿瘤演化过程中的进化生态：概念、应用与创新

刘灿¹^,²^,⁴(), 翟巍巍³^,⁴, 吕雪梅¹^,²^,⁴()

1.中国科学院昆明动物研究所，遗传进化与动物模型重点实验室，昆明 650201
2.云南省西南及跨境生物多样性数据信息重点实验室，昆明 650201
3.中国科学院动物研究所，动物进化与系统学院重点实验室，北京 100101
4.中国科学院大学，北京 101408

收稿日期:2024-09-13 修回日期:2024-11-05 出版日期:2025-02-20 发布日期:2024-11-26
通讯作者: 吕雪梅，博士，研究员，研究方向：物种适应性进化与肿瘤演化。E-mail: xuemeilu@mail.kiz.ac.cn
作者简介:刘灿，硕士研究生，专业方向：肿瘤进化遗传学。E-mail: liucan@mail.kiz.ac.cn
基金资助:
国家自然科学基金项目(32150006)

Evolutionary ecology in tumor evolution: concept, application and innovation

Can Liu¹^,²^,⁴(), Weiwei Zhai³^,⁴, Xuemei Lu¹^,²^,⁴()

1. Key Laboratory of Genetic Evolution & Animal Models, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650201, China
2. Yunnan Key Laboratory of Biodiversity Information, Kunming 650201, China
3. Key Laboratory of Zoological Systematics and Evolution, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China
4. University of Chinese Academy of Sciences, Beijing 101408, China

Received:2024-09-13 Revised:2024-11-05 Published:2025-02-20 Online:2024-11-26
Supported by:
National Natural Science Foundation of China(32150006)

摘要/Abstract

摘要：

肿瘤本身是一个复杂的微生态系统，存在复杂时空动态和多维度的互作关系，其超乎想象的异质性与演化能力已经超出了传统肿瘤医学的认知。如何系统性地从物质、能量、信号多层面上的动态、互作去刻画整个肿瘤的细胞生态圈，以期从中挖掘对肿瘤发生发展的新认知、新规律和新疗法，是肿瘤生态学新的命题和目标。本文从进化生态的角度探讨肿瘤的起源与发生发展规律，首先探讨了生态学的一些经典概念在肿瘤演化中的应用；随后通过整合前沿的肿瘤生态学进展从癌细胞之间、癌细胞与其他正常体细胞之间、肿瘤生态系统等多层次，揭示了生态互作对肿瘤发生发展的重要性。最后基于以上论述，提出肿瘤的细胞生态圈的概念，并探讨了后续如何从系统论刻画整个肿瘤生态系统并提出可能的创新治疗方向。

关键词: 肿瘤演化, 进化生态, 生态互作, 细胞群体动态, 肿瘤生态圈

Abstract:

Tumor itself is a complex microecosystem, with complex spatio-temporal dynamics and multi-dimensional interactions. Its unimaginable heterogeneity and evolvability have exceeded the cognition of traditional oncology medicine. How to systematically characterize the whole tumor cell ecosystem from the dynamics and interaction of material, energy and signal levels, in order to explore new cognition, new rules and new therapies for the occurrence and development of tumors, is a new proposition and goal of tumor ecology. In this review, we discuss the origin, occurrence and development of tumors from the perspective of evolutionary ecology. First, we discuss the application of some classical concepts of ecology with tumor evolution. Subsequently, through the integration of the frontier papers of tumor ecology, we highlight the importance of ecological interactions on the occurrence and development of tumors from multiple levels, such as between cancer cells, between cancer cells and other normal somatic cells, and the tumor ecosystem. Finally, we propose the concept of tumor cell ecosystem, discussed how to characterize the entire tumor ecosystem from the system theory and proposed possible innovative treatment directions.

Key words: tumor evolution, evolutionary ecology, ecological interaction, cell population dynamics, tumor ecosphere

刘灿, 翟巍巍, 吕雪梅. 肿瘤演化过程中的进化生态：概念、应用与创新[J]. 遗传, 2025, 47(2): 228-236.

Can Liu, Weiwei Zhai, Xuemei Lu. Evolutionary ecology in tumor evolution: concept, application and innovation[J]. Hereditas(Beijing), 2025, 47(2): 228-236.

图/表 1

参考文献 63

[1]	Boveri T. The Origin of Malignant Tumors. Williams & Wilkins, 1929.
[2]	Nowell PC. The clonal evolution of tumor cell populations. Science, 1976, 194(4260): 23-28. doi: 10.1126/science.959840 pmid: 959840
[3]	Cairns J. Mutation selection and the natural history of cancer. Nature, 1975, 255(5505): 197-200.
[4]	Li WH. Molecular Evolution. Sinauer Associates: Sunderland, Mass, 1997.
[5]	Hartl DL, Clark AG. Principles of Population Genetics. Sinauer Associates, Inc., 2007.
[6]	Maley CC, Aktipis A, Graham TA, Sottoriva A, Boddy AM, Janiszewska M, Silva AS, Gerlinger M, Yuan YY, Pienta KJ, Anderson KS, Gatenby R, Swanton C, Posada D, Wu CI, Schiffman JD, Hwang ES, Polyak K, Anderson ARA, Brown JS, Greaves M, Shibata D. Classifying the evolutionary and ecological features of neoplasms. Nat Rev Cancer, 2017, 17(10): 605-619. doi: 10.1038/nrc.2017.69 pmid: 28912577
[7]	Merlo LMF, Pepper JW, Reid BJ, Maley CC. Cancer as an evolutionary and ecological process. Nat Rev Cancer, 2006, 6(12): 924-935. doi: 10.1038/nrc2013 pmid: 17109012
[8]	Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer, 2012, 12(5): 323-334. doi: 10.1038/nrc3261 pmid: 22513401
[9]	Ling SP, Hu Z, Yang ZY, Yang F, Li YW, Lin P, Chen K, Dong LL, Cao LH, Tao Y, Hao LT, Chen QJ, Gong Q, Wu DF, Li WJ, Zhao WM, Tian XY, Hao CY, Hungate EA, Catenacci DVT, Hudson RR, Li WH, Lu XM, Wu CI. Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution. Proc Natl Acad Sci USA, 2015, 112(47): E6496-E6505.
[10]	Wu CI, Wang HY, Ling SP, Lu XM. The ecology and evolution of cancer: the ultra-microevolutionary process. Annu Rev Genet, 2016, 50(1): 347-369.
[11]	Li GH, Yang ZY, Wu DF, Liu SX, Li XN, Li T, Li YW, Liang LJ, Zou WL, Wu CI, Wang HY, Lu XM. Evolution under spatially heterogeneous selection in solid tumors. Mol Biol Evol, 2022, 39(1): msab335.
[12]	Sun RP, Hu Z, Curtis C. Big bang tumor growth and clonal evolution. Cold Spring Harb Perspect Med, 2018, 8(5): a028381.
[13]	Aran D, Camarda R, Odegaard J, Paik H, Oskotsky B, Krings G, Goga A, Sirota M, Butte AJ. Comprehensive analysis of normal adjacent to tumor transcriptomes. Nat Commun, 2017, 8(1): 1077. doi: 10.1038/s41467-017-01027-z pmid: 29057876
[14]	Bartman CR, Weilandt DR, Shen YH, Lee WD, Han YJ, TeSlaa T, Jankowski CSR, Samarah L, Park NR, da Silva-Diz V, Aleksandrova M, Gultekin Y, Marishta A, Wang L, Yang LF, Roichman A, Bhatt V, Lan TJ, Hu ZX, Xing X, Lu WY, Davidson S, Wühr M, Vander Heiden MG, Herranz D, Guo JYX, Kang YB, Rabinowitz JD. Slow TCA flux and ATP production in primary solid tumours but not metastases. Nature, 2023, 614(7947): 349-357.
[15]	Zhang SS, Xiao XY, Yi YL, Wang XY, Zhu LX, Shen YR, Lin DX, Wu C. Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets. Signal Transduct Target Ther, 2024, 9(1): 1-36.
[16]	Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primers, 2021, 7(1): 1-20.
[17]	Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, Petrella F, Spaggiari L, Rosell R. Non-small-cell lung cancer. Nat Rev Dis Primers, 2015, 1(1): 1-16.
[18]	Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov, 2022, 12(1): 31-46. doi: 10.1158/2159-8290.CD-21-1059 pmid: 35022204
[19]	Anderson NM, Simon MC. The tumor microenvironment. Curr Biol, 2020, 30(16): R921-R925.
[20]	Liu XD, Zhang K, Kaya NA, Jia Z, Wu DF, Chen TT, Liu ZY, Zhu SN, Hillmer AM, Wuestefeld T, Liu J, Chan YS, Hu Z, Ma L, Jiang L, Zhai WW. Tumor phylogeography reveals block-shaped spatial heterogeneity and the mode of evolution in hepatocellular carcinoma. Nat Commun, 2024, 15(1): 3169. doi: 10.1038/s41467-024-47541-9 pmid: 38609353
[21]	Aktipis CA, Boddy AM, Gatenby RA, Brown JS, Maley CC. Life history trade-offs in cancer evolution. Nat Rev Cancer, 2013, 13(12): 883-892. doi: 10.1038/nrc3606 pmid: 24213474
[22]	Li T, Liu JL, Feng J, Liu ZZ, Liu SX, Zhang MJ, Zhang YZ, Hou YL, Wu DF, Li CY, Chen YB, Chen H, Lu XM. Variation in the life history strategy underlies functional diversity of tumors. Nat Sci Rev, 2021, 8(2): nwaa124.
[23]	Vidal P. Interferon α in cancer immunoediting: from elimination to escape. Scand J Immunol, 2020, 91(5): e12863.
[24]	Zamarron BF, Chen WJ. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci, 2011, 7(5): 651-658. doi: 10.7150/ijbs.7.651 pmid: 21647333
[25]	Manjili MH, Najarian K, Wang XY. Signatures of tumor-immune interactions as biomarkers for breast cancer prognosis. Future Oncol, 2012, 8(6): 703-711. doi: 10.2217/fon.12.57 pmid: 22764768
[26]	Bruni D, Angell HK, Galon J. The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer, 2020, 20(11): 662-680.
[27]	Pelham CJ, Nagane M, Madan E. Cell competition in tumor evolution and heterogeneity: merging past and present. Semin Cancer Biol, 2020, 63: 11-18. doi: S1044-579X(19)30071-9 pmid: 31323289
[28]	Chang CH, Qiu J, O’Sullivan D, Buck MD, Noguchi T, Curtis JD, Chen QY, Gindin M, Gubin MM, van der Windt GJW, Tonc E, Schreiber RD, Pearce EJ, Pearce EL. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell, 2015, 162(6): 1229-1241.
[29]	Chen Y, McAndrews KM, Kalluri R. Clinical and therapeutic relevance of cancer-associated fibroblasts. Nat Rev Clin Oncol, 2021, 18(12): 792-804. doi: 10.1038/s41571-021-00546-5 pmid: 34489603
[30]	Xing F, Saidou J, Watabe K. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci (Landmark Ed), 2010, 15(1): 166-179. doi: 10.2741/3613 pmid: 20036813
[31]	Qin X, Cardoso Rodriguez F, Sufi J, Vlckova P, Claus J, Tape CJ. An oncogenic phenoscape of colonic stem cell polarization. Cell, 2023, 186(25): 5554.e18-5568.e18.
[32]	Gunaydin G. CAFs interacting with TAMs in tumor microenvironment to enhance tumorigenesis and immune evasion. Front Oncol, 2021, 11: 668349.
[33]	Shakiba N, Fahmy A, Jayakumaran G, McGibbon S, David L, Trcka D, Elbaz J, Puri MC, Nagy A, van der Kooy D, Goyal S, Wrana JL, Zandstra PW. Cell competition during reprogramming gives rise to dominant clones. Science, 2019, 364(6438): eaan0925.
[34]	Di Giacomo S, Sollazzo M, de Biase D, Ragazzi M, Bellosta P, Pession A, Grifoni D. Human cancer cells signal their competitive fitness through MYC activity. Sci Rep, 2017, 7(1): 12568.
[35]	Yan BW, Chen QW, Xu JF, Li W, Xu B, Qiu Y. Low-frequency TP53 hotspot mutation contributes to chemoresistance through clonal expansion in acute myeloid leukemia. Leukemia, 2020, 34(7): 1816-1827. doi: 10.1038/s41375-020-0710-7 pmid: 31988438
[36]	Yang D, Jones MG, Naranjo S, Rideout WM 3rd, Min KHJ Ho R, Wu W, Replogle JM, Page JL, Quinn JJ, Horns F, Qiu XJ, Chen MZ, Freed-Pastor WA, McGinnis CS, Patterson DM, Gartner ZJ, Chow ED, Bivona TG, Chan MM, Yosef N, Jacks T, Weissman JS. Lineage tracing reveals the phylodynamics, plasticity, and paths of tumor evolution. Cell, 2022, 185(11): 1905.e25-1923.e25.
[37]	Armstrong RA, McGehee R. Competitive exclusion. Am Nat, 1980, 115(2): 151-170.
[38]	Carneiro TNR, Bim LV, Buzatto VC, Galdeno V, Asprino PF, Lee EA, Galante PAF, Cerutti JM. Evidence of cooperation between hippo pathway and RAS mutation in thyroid carcinomas. Cancers (Basel), 2021, 13(10): 2306.
[39]	Masroni MSB, Lee KW, Lee VKM, Ng SB, Law CT, Poon KS, Lee BTK, Liu ZH, Tan YP, Chng WL, Tucker S, Ngo LSM, Yip GWC, Nga ME, Hue SSS, Putti TC, Bay BH, Lin QS, Zhou LH, Hartman M, Loh TP, Lakshmanan M, Lee SY, Tergaonkar V, Chua H, Lee AVH, Yeo EYM, Li MH, Chang CF, Kee ZZ, Tan KML, Tan SY, Koay ESC, Archetti M, Leong SM. Dynamic altruistic cooperation within breast tumors. Mol Cancer, 2023, 22(1): 206.
[40]	Benzekry S, Lamont C, Beheshti A, Tracz A, Ebos JML, Hlatky L, Hahnfeldt P. Classical mathematical models for description and prediction of experimental tumor growth. PLoS Comput Biol, 2014, 10(8): e1003800.
[41]	Rodriguez-Brenes IA, Komarova NL, Wodarz D. Tumor growth dynamics: insights into evolutionary processes. Trends Ecol Evol, 2013, 28(10): 597-604. doi: 10.1016/j.tree.2013.05.020 pmid: 23816268
[42]	Mandonnet E, Delattre JY, Tanguy ML, Swanson KR, Carpentier AF, Duffau H, Cornu P, Van Effenterre R, Alvord EC Jr, Capelle L. Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol, 2003, 53(4): 524-528. doi: 10.1002/ana.10528 pmid: 12666121
[43]	Hart D, Shochat E, Agur Z. The growth law of primary breast cancer as inferred from mammography screening trials data. Br J Cancer, 1998, 78(3): 382-387.
[44]	Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E, Germani M, Poggesi I, Rocchetti M. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res, 2004, 64(3): 1094-1101. pmid: 14871843
[45]	Hodis E, Triglia ET, Kwon JYH, Biancalani T, Zakka LR, Parkar S, Hütter JC, Buffoni L, Delorey TM, Phillips D, Dionne D, Nguyen LT, Schapiro D, Maliga Z, Jacobson CA, Hendel A, Rozenblatt-Rosen O, Mihm MC Jr, Garraway LA, Regev A. Stepwise-edited. human melanoma models reveal mutations’ effect on tumor and microenvironment. Science, 2022, 376(6592): eabi8175.
[46]	Zhang YR, Zhang B, Lv CQ, Zhang N, Xing KY, Wang ZX, Lv RK, Yu MC, Xu CH, Wang YH. Single-cell RNA sequencing identifies critical transcription factors of tumor cell invasion induced by hypoxia microenvironment in glioblastoma. Theranostics, 2023, 13(11): 3744-3760. doi: 10.7150/thno.81407 pmid: 37441593
[47]	Li T. Ecological adaptation of tumor cells--density- dependent selection and adaptivity trade-off [Dissertation]. Beijing Institute of Genome, Chinese Academy of Sciences, 2019.
	李涛. 肿瘤细胞的生态适应——密度依赖性选择和适应性权衡[学位论文]. 中国科学院北京基因组研究所, 2019.
[48]	Hui S, Ghergurovich JM, Morscher RJ, Jang C, Teng X, Lu WY, Esparza LA, Reya T, Le Zhan, Yanxiang Guo J, White E, Rabinowitz JD. Glucose feeds the TCA cycle via circulating lactate. Nature, 2017, 551(7678): 115-118.
[49]	Laplane L, Maley CC. The evolutionary theory of cancer: challenges and potential solutions. Nat Rev Cancer, 2024, 24(10): 718-733. doi: 10.1038/s41568-024-00734-2 pmid: 39256635
[50]	Krieger TG, Le Blanc S, Jabs J, Ten FW, Ishaque N, Jechow K, Debnath O, Leonhardt C-S, Giri A, Eils R, Strobel O, Conrad C. Single-cell analysis of patient- derived PDAC organoids reveals cell state heterogeneity and a conserved developmental hierarchy. Nat Commun, 2021, 12(1): 5826.
[51]	Lorenzo-Martín LF, Hübscher T, Bowler AD, Broguiere N, Langer J, Tillard L, Nikolaev M, Radtke F, Lutolf MP. Spatiotemporally resolved colorectal oncogenesis in mini-colons ex vivo. Nature, 2024, 629(8011): 450-457.
[52]	Mitrofanova O, Nikolaev M, Xu Q, Broguiere N, Cubela I, Camp JG, Bscheider M, Lutolf MP. Bioengineered human colon organoids with in vivo-like cellular complexity and function. Cell Stem Cell, 2024, 31(8): 1175.e7-1186.e7.
[53]	Ruiz-Moreno C, Salas SM, Samuelsson E, Brandner S, Kranendonk MEG, Nilsson M, Stunnenberg HG. Harmonized single-cell landscape, intercellular crosstalk and tumor architecture of glioblastoma. bioRxiv, 2022, https://doi.org/10.1101/2022.08.27.505439.
[54]	Gavish A, Tyler M, Greenwald AC, Hoefflin R, Simkin D, Tschernichovsky R, Galili Darnell N, Somech E, Barbolin C, Antman T, Kovarsky D, Barrett T, Gonzalez Castro LN, Halder D, Chanoch-Myers R, Laffy J, Mints M, Wider A, Tal R, Spitzer A, Hara T, Raitses-Gurevich M, Stossel C, Golan T, Tirosh A, Suvà ML, Puram SV, Tirosh I. Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours. Nature, 2023, 618(7965): 598-606.
[55]	Kinker GS, Greenwald AC, Tal R, Orlova Z, Cuoco MS, McFarland JM, Warren A, Rodman C, Roth JA, Bender SA, Kumar B, Rocco JW, Fernandes PACM, Mader CC, Keren-Shaul H, Plotnikov A, Barr H, Tsherniak A, Rozenblatt-Rosen O, Krizhanovsky V, Puram SV, Regev A, Tirosh I. Pan-cancer single-cell RNA-seq identifies recurring programs of cellular heterogeneity. Nat Genet, 2020, 52(11): 1208-1218. doi: 10.1038/s41588-020-00726-6 pmid: 33128048
[56]	Zhu QH, Zhao X, Zhang YH, Li YP, Liu S, Han JX, Sun ZY, Wang CQ, Deng DQ, Wang SS, Tang YS, Huang YL, Jiang SY, Tian C, Chen X, Yuan Y, Li ZY, Yang T, Lai TT, Liu YQ, Yang WZ, Zou XX, Zhang MY, Cui HH, Liu CY, Jin X, Hu YH, Chen A, Xu X, Li GP, Hou Y, Liu LQ, Liu SP, Fang L, Chen W, Wu L. Single cell multi-omics reveal intra-cell-line heterogeneity across human cancer cell lines. Nat Commun, 2023, 14(1): 8170. doi: 10.1038/s41467-023-43991-9 pmid: 38071219
[57]	Marine JC, Dawson SJ, Dawson MA. Non-genetic mechanisms of therapeutic resistance in cancer. Nat Rev Cancer, 2020, 20(12): 743-756.
[58]	França GS, Baron M, King BR, Bossowski JP, Bjornberg A, Pour M, Rao A, Patel AS, Misirlioglu S, Barkley D, Tang, KH, Dolgalev I, Liberman DA, Avital G, Kuperwaser F, Chiodin M, Levine DA, Papagiannakopoulos T, Marusyk A, Lionnet T, Yanai I. Cellular adaptation to cancer therapy along a resistance continuum. Nature, 2024, 631(8022): 876-883.
[59]	Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SGH, Hoadley KA, Rashid NU, Williams LA, Eaton SC, Chung AH, Smyla JK, Anderson JM, Kim HJ, Bentrem DJ, Talamonti MS, Iacobuzio-Donahue CA, Hollingsworth MA, Yeh JJ. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet, 2015, 47(10): 1168-1178. doi: 10.1038/ng.3398 pmid: 26343385
[60]	Oh K, Yoo YJ, Torre-Healy LA, Rao M, Fassler D, Wang P, Caponegro M, Gao M, Kim J, Sasson A, Georgakis G, Powers S, Moffitt RA. Coordinated single-cell tumor microenvironment dynamics reinforce pancreatic cancer subtype. Nat Commun, 2023, 14(1): 5226. doi: 10.1038/s41467-023-40895-6 pmid: 37633924
[61]	Najafi M, Goradel NH, Farhood B, Salehi E, Solhjoo S, Toolee H, Kharazinejad E, Mortezaee K. Tumor microenvironment: interactions and therapy. J Cell Physiol, 2019, 234(5): 5700-5721. doi: 10.1002/jcp.27425 pmid: 30378106
[62]	Xiao Y, Yu DH. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther, 2021, 221: 107753.
[63]	Hu B, Zou Y, Zhang LL, Tang JX, Niedermann G, Firat E, Huang XX, Zhu XK. Nucleofection with plasmid DNA for CRISPR/Cas9-mediated inactivation of programmed cell death protein 1 in CD133-specific CAR T cells. Hum Gene Ther, 2019, 30(4): 446-458. doi: 10.1089/hum.2017.234 pmid: 29706119

编辑推荐

Metrics

www.chinagene.cn
备案号：京ICP备09063187号-4
总访问:,今日访问:,当前在线:

肿瘤演化过程中的进化生态：概念、应用与创新

Evolutionary ecology in tumor evolution: concept, application and innovation

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 63

相关文章 0

编辑推荐

Metrics